News

You are here

May 29, 2015

On Tuesday 16th of June 2015, Iproteos will celebrate an Ordinary General Meeting. More information is given in the link below. El martes 16 de Enero de 2015, Iproteos celebrará una Junta General Ordinaria. Se puede encontrar toda la información necesaria en el siguiente enlace: CONVOCATORIA JUNTA GENERAL IPROTEOS 16 DE JUNIO 2015

May 05, 2015

The biotech Iproteos participates in a project co-funded by the European Union’s Horizon 2020 research and innovation programme under a Marie Sklodowska-Curie grant (No. 645881). The project, called ECMED (Extracellular Matrix in Epileptogenesis), is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy. It has a duration of three years and a budget of € 3.5 million. Around 50 million people worldwide suffer from epilepsy, according to WHO.

Apr 28, 2015

JOB TITLE:                   Early Stage Researcher (ESR)                                                               Company:                   Iproteos Supervised by:      Dr. Teresa Tarragó Area of study:         This position is funded by a Marie Curie Initial Training Network Initiative.

Feb 10, 2015

Roger Prades, Iproteos CSO, is the first author of an article published this January at Angewandte Chemie reporting a novel peptide capable of overcoming the blood-brain barrier. The work has been possible through the collaboration of a team composed by scientists at IRB Barcelona, RCSI, ISD, INA and UB. The BBB-shuttle is a retro-enantio peptide that is protease-resistant, non-toxic and has the ability of transporting cargos of distinct sizes and types across this barrier. It targets the transferrin receptor but it does not compete with transferrin. Therefore, the peptide reported by Dr.

Feb 10, 2015

Ernest Giralt, co-founder of Iproteos, has been awarded with the “Barcelona City” 2014 prize in the category of Experimental Sciences and Technology. The jury has recognized Prof. Giralt for his development of a technology that allows a cytotoxic peptide from the bee poison to target only tumor cells, without affecting the healthy ones, being therefore, a therapeutic approach with application in chemotherapy. The award ceremony has taken place today, 2 days before “Santa Eulàlia day” – Patron Saint of Barcelona.

Feb 10, 2015

The project named “Spark”, which is devoted to the development of a drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia, has obtained a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1645-1).